Erasca Inc (ERAS)
Healthcare
Biotechnology
18.20 $
-2.8%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Erasca Inc (ERAS)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 66.8% of the shares are freely tradable; institutional investors hold 93.3%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
93.3%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
10.7%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
66.8%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
11.4%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
311Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 7.93 | 24,675,188 | +8.6 | 03/31/2026 |
| T. Rowe Price Investment Management,Inc. | 6.84 | 21,259,646 | +1.7 | 03/31/2026 |
| BlackRock Inc | 6.48 | 20,151,406 | +29.2 | 03/31/2026 |
| VR Adviser, LLC | 5.27 | 16,382,812 | -8.3 | 03/31/2026 |
| RTW INVESTMENTS, LLC | 5.20 | 16,157,175 | +10,917.4 | 03/31/2026 |
| Vanguard Group Inc | 4.12 | 12,812,156 | +0.0 | 12/31/2025 |
| Vivo Capital, LLC | 3.91 | 12,151,480 | +31.0 | 03/31/2026 |
| Vanguard Capital Management, LLC | 3.62 | 11,249,738 | +0.0 | 03/31/2026 |
| Siren, L.L.C. | 3.62 | 11,244,246 | +28.4 | 03/31/2026 |
| Logos Global Management LP | 3.59 | 11,150,000 | -14.2 | 03/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.